BRPI0823082B8 - composições de derivados de sesquiterpeno para prevenir ou tratar hiperlipidemia, fígado gordo, diabetes ou obesidade - Google Patents

composições de derivados de sesquiterpeno para prevenir ou tratar hiperlipidemia, fígado gordo, diabetes ou obesidade

Info

Publication number
BRPI0823082B8
BRPI0823082B8 BRPI0823082A BRPI0823082A BRPI0823082B8 BR PI0823082 B8 BRPI0823082 B8 BR PI0823082B8 BR PI0823082 A BRPI0823082 A BR PI0823082A BR PI0823082 A BRPI0823082 A BR PI0823082A BR PI0823082 B8 BRPI0823082 B8 BR PI0823082B8
Authority
BR
Brazil
Prior art keywords
obesity
diabetes
fatty liver
sesquiterpene
hyperlipidemia
Prior art date
Application number
BRPI0823082A
Other languages
English (en)
Inventor
Kim Ha-Won
Park Tae-Sun
Original Assignee
Kwang Dong Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kwang Dong Pharm Co Ltd filed Critical Kwang Dong Pharm Co Ltd
Publication of BRPI0823082A2 publication Critical patent/BRPI0823082A2/pt
Publication of BRPI0823082B1 publication Critical patent/BRPI0823082B1/pt
Publication of BRPI0823082B8 publication Critical patent/BRPI0823082B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

uso de derivados de sesquiterpeno a presente invenção se refere a uma composição farmacêutica para prevenir ou tratar hiperlipidemia, fígado gordo, diabetes e obesidade que compreende um derivado de sesquiterpeno como um ingrediente ativo. os derivados de sesquiterpeno da presente invenção levam à diminuição em peso de gordura corporal, peso de gordura visceral e níveis de colesterol totais, triglicerídeo de plasma e tecido do fígado, níveis de glicose sanguínea e insulina sanguínea em um estado rápido, exibindo finalmente eficácias em prevenção ou tratamento de hiperlipidemia, fígado gordo, diabetes e obesidade. a presente invenção se refere a uma composição farmacêutica para prevenir ou tratar hiperlipidemia, fígado gordo, diabetes e obesidade que compreende um derivado de sesquiterpeno como um ingrediente ativo. os derivados de sesquiterpeno da presente invenção levam à diminuição em peso de gordura corporal, peso de gordura visceral e níveis de colesterol totais, triglicerídeo de plasma e tecido do fígado, níveis de glicose sanguínea e insulina sanguínea em um estado rápido, exibindo finalmente eficácias em prevenção ou tratamento de hiperlipidemia, fígado gordo, diabetes e obesidade.
BRPI0823082A 2008-09-11 2008-10-20 composições de derivados de sesquiterpeno para prevenir ou tratar hiperlipidemia, fígado gordo, diabetes ou obesidade BRPI0823082B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2008-0089971 2008-09-11
KR1020080089971A KR100905419B1 (ko) 2008-09-11 2008-09-11 세스퀴테르펜 유도체의 용도
PCT/KR2008/006198 WO2010030054A2 (en) 2008-09-11 2008-10-20 Uses of sesquiterpene derivatives

Publications (3)

Publication Number Publication Date
BRPI0823082A2 BRPI0823082A2 (pt) 2015-06-16
BRPI0823082B1 BRPI0823082B1 (pt) 2019-02-26
BRPI0823082B8 true BRPI0823082B8 (pt) 2021-05-25

Family

ID=41337139

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0823082A BRPI0823082B8 (pt) 2008-09-11 2008-10-20 composições de derivados de sesquiterpeno para prevenir ou tratar hiperlipidemia, fígado gordo, diabetes ou obesidade

Country Status (9)

Country Link
US (1) US8481592B2 (pt)
EP (1) EP2331089B1 (pt)
JP (1) JP5435375B2 (pt)
KR (1) KR100905419B1 (pt)
CN (1) CN102143741B (pt)
BR (1) BRPI0823082B8 (pt)
ES (1) ES2560533T3 (pt)
MX (1) MX2011001594A (pt)
WO (1) WO2010030054A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2345646A1 (en) * 2010-01-14 2011-07-20 InterMed Discovery GmbH Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
KR101138565B1 (ko) * 2010-03-25 2012-05-10 동아제약주식회사 비만 또는 지질 관련 대사성 질환의 치료 또는 예방용 조성물
US20150246087A1 (en) * 2012-06-11 2015-09-03 Regenera Pharma Ltd. Extracts and therapeutic uses thereof
CN103626636B (zh) 2013-11-06 2015-04-08 中国科学院南海海洋研究所 一种链霉倍半萜三醇及其制备方法和应用
EP3197422A1 (en) 2014-09-26 2017-08-02 The Procter & Gamble Company Cleaning and/or treatment compositions comprising malodor reduction compositions
JP6861708B2 (ja) * 2015-12-30 2021-04-21 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 除脂肪体重を測定するための方法
WO2017165615A1 (en) 2016-03-24 2017-09-28 The Procter & Gamble Company Hair care compositions comprising malodor reduction compositions
KR101674622B1 (ko) * 2016-07-07 2016-11-09 국민대학교산학협력단 세스퀴테르펜 유도체의 신규한 용도
KR102061933B1 (ko) * 2017-06-23 2020-01-02 연세대학교 산학협력단 세스퀴테르펜 유도체를 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물
EP3694607B1 (en) 2017-10-10 2022-12-28 The Procter & Gamble Company Compact shampoo composition
US10792384B2 (en) 2017-12-15 2020-10-06 The Procter & Gamble Company Rolled fibrous structures comprising encapsulated malodor reduction compositions
KR20210022504A (ko) * 2019-08-20 2021-03-03 엠에프씨 주식회사 신규 세스퀴테르펜 유도체(1) 및 이의 용도
WO2021173203A1 (en) 2020-02-27 2021-09-02 The Procter & Gamble Company Anti-dandruff compositions with sulfur having enhanced efficacy and aesthetics
CN112245416A (zh) * 2020-11-17 2021-01-22 广西馨海药业科技有限公司 Pinnatifolone A在制备具有镇静、催眠作用药物中的应用及药物组合物
CN116568263A (zh) 2020-12-04 2023-08-08 宝洁公司 包含恶臭减少材料的毛发护理组合物
KR102383733B1 (ko) * 2021-02-18 2022-04-11 고려대학교 산학협력단 세스퀴테르펜 유도체를 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학적 조성물
US11771635B2 (en) 2021-05-14 2023-10-03 The Procter & Gamble Company Shampoo composition
CN115282131B (zh) * 2022-07-26 2023-10-10 东莞广州中医药大学研究院 一种治疗非酒精性脂肪肝的药物组合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US702722A (en) 1901-11-21 1902-06-17 William Gorman Heating-furnace.
JP3113759B2 (ja) * 1993-05-17 2000-12-04 花王株式会社 セスキテルペン誘導体
ES2179520T3 (es) * 1997-07-24 2003-01-16 Zografos Dietetic Products S A Utilizaciones farmaceuticas del cipres.
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
FR2773079B1 (fr) 1997-12-30 2002-05-17 Itzik Harosh Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii
US6380224B1 (en) 1999-07-28 2002-04-30 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
JP2001247461A (ja) * 2000-03-03 2001-09-11 Zenyaku Kogyo Kk 糖尿病予防・改善剤
US6680387B2 (en) 2000-04-24 2004-01-20 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
US6987131B1 (en) 2000-06-26 2006-01-17 Burzynski Stanislaw R Phenylacetic acid compositions for treating or preventing hypercholesterolemia
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050271755A1 (en) 2004-05-12 2005-12-08 Ilya Raskin Phytomedicinal compositions for the control of lipid accumulation and metabolism in mammals
JP2006241287A (ja) * 2005-03-02 2006-09-14 Suntory Ltd 脂質代謝改善作用を有する組成物
KR100711028B1 (ko) * 2005-07-13 2007-04-24 한국생명공학연구원 향나무 추출물 또는 세드롤을 포함하는 비만 및 제2형당뇨병 예방 및 치료용 조성물
WO2007066305A1 (en) * 2005-12-09 2007-06-14 Zelpy 2549 (Pty) Limited Compositions comprising sesquiterpene compounds for use in the prophylaxis or treatment of pain

Also Published As

Publication number Publication date
US8481592B2 (en) 2013-07-09
JP2012502094A (ja) 2012-01-26
ES2560533T3 (es) 2016-02-19
CN102143741A (zh) 2011-08-03
BRPI0823082B1 (pt) 2019-02-26
EP2331089B1 (en) 2015-12-16
WO2010030054A3 (en) 2010-07-15
KR100905419B1 (ko) 2009-07-02
CN102143741B (zh) 2013-09-11
WO2010030054A2 (en) 2010-03-18
MX2011001594A (es) 2011-06-27
BRPI0823082A2 (pt) 2015-06-16
US20120129924A1 (en) 2012-05-24
JP5435375B2 (ja) 2014-03-05
EP2331089A4 (en) 2011-12-21
EP2331089A2 (en) 2011-06-15

Similar Documents

Publication Publication Date Title
BRPI0823082B8 (pt) composições de derivados de sesquiterpeno para prevenir ou tratar hiperlipidemia, fígado gordo, diabetes ou obesidade
BR112013016021A2 (pt) métodos e composições adequadas para gerenciar glicemia em animais
PH12018501424B1 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
BR122019016628B8 (pt) uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
BR112016027469A2 (pt) composição para tratamento de diabetes que compreende conjugado de análogo de insulina de ação lenta e conjugado de peptídeo insulinotrópico de ação lenta
WO2009007412A3 (fr) Deglycation des ages
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
BR112012006010A2 (pt) composto de glicina
CO6341563A2 (es) Compuestos organicos
BR112017021311A2 (pt) composições farmacêuticas para terapia de combinação
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
BR112013006396A2 (pt) composições imunogênicas
MX2009002921A (es) Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
BR112012011478A2 (pt) composições fosfolipídicas terapêuticas concentradas.
WO2011018501A3 (en) Composition including an unsaponifiable fraction
MX2011008448A (es) Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
BRPI0622054B8 (pt) composto e composição farmacêutica
CR9989A (es) Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero
RU2009133338A (ru) Композиции, содержащие экстракты cynara scolymus и phaseolus vulgaris, которые полезны для лечения ожирения
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BRPI0908194B8 (pt) Uso de uma anexina a5 recombinante, e stent de eluição de fármaco

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/02/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF